Christopher Raymond
Stock Analyst at Raymond James
(2.70)
# 1,855
Out of 5,182 analysts
140
Total ratings
53.04%
Success rate
2.03%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALMS Alumis | Initiates: Strong Buy | $46 | $24.93 | +84.52% | 1 | Mar 11, 2026 | |
| CLYM Climb Bio | Initiates: Strong Buy | $25 | $9.14 | +173.52% | 1 | Mar 11, 2026 | |
| COGT Cogent Biosciences | Maintains: Overweight | $39 → $52 | $36.81 | +41.27% | 2 | Feb 18, 2026 | |
| ARDX Ardelyx | Upgrades: Overweight | $10 → $16 | $5.95 | +168.91% | 11 | Jan 9, 2026 | |
| LXEO Lexeo Therapeutics | Initiates: Strong Buy | $25 | $5.85 | +327.35% | 1 | Dec 18, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Strong Buy | $13 | $6.40 | +103.13% | 3 | Oct 21, 2025 | |
| MGTX MeiraGTx Holdings | Initiates: Strong Buy | $29 | $9.23 | +214.19% | 2 | Oct 21, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $42 → $70 | $114.56 | -38.90% | 2 | Jul 23, 2025 | |
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $184.38 | -37.63% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $1.67 | +438.92% | 6 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $122 → $126 | $53.18 | +136.93% | 15 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $4 | $6.22 | -35.69% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $227 | $198.71 | +14.24% | 12 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $535 → $533 | $430.29 | +23.87% | 8 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,195 → $1,013 | $751.57 | +34.78% | 7 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $24.10 | +480.91% | 5 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $53.20 | +35.34% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $4.30 | +202.33% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $8.66 | +766.05% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $9.88 | +669.23% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $37.59 | -12.21% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $1.43 | +179.72% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $344.55 | -16.41% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $25.32 | +61.93% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $36.25 | -22.76% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $104.50 | -61.72% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $7.92 | +1,036.36% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $1.15 | +8,247.83% | 2 | Mar 13, 2020 |
Alumis
Mar 11, 2026
Initiates: Strong Buy
Price Target: $46
Current: $24.93
Upside: +84.52%
Climb Bio
Mar 11, 2026
Initiates: Strong Buy
Price Target: $25
Current: $9.14
Upside: +173.52%
Cogent Biosciences
Feb 18, 2026
Maintains: Overweight
Price Target: $39 → $52
Current: $36.81
Upside: +41.27%
Ardelyx
Jan 9, 2026
Upgrades: Overweight
Price Target: $10 → $16
Current: $5.95
Upside: +168.91%
Lexeo Therapeutics
Dec 18, 2025
Initiates: Strong Buy
Price Target: $25
Current: $5.85
Upside: +327.35%
Taysha Gene Therapies
Oct 21, 2025
Initiates: Strong Buy
Price Target: $13
Current: $6.40
Upside: +103.13%
MeiraGTx Holdings
Oct 21, 2025
Initiates: Strong Buy
Price Target: $29
Current: $9.23
Upside: +214.19%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Overweight
Price Target: $42 → $70
Current: $114.56
Upside: -38.90%
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $184.38
Upside: -37.63%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $1.67
Upside: +438.92%
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $53.18
Upside: +136.93%
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $6.22
Upside: -35.69%
Jan 27, 2025
Maintains: Overweight
Price Target: $220 → $227
Current: $198.71
Upside: +14.24%
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $430.29
Upside: +23.87%
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $751.57
Upside: +34.78%
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $24.10
Upside: +480.91%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $53.20
Upside: +35.34%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $4.30
Upside: +202.33%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $8.66
Upside: +766.05%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $9.88
Upside: +669.23%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $37.59
Upside: -12.21%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $1.43
Upside: +179.72%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $344.55
Upside: -16.41%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $25.32
Upside: +61.93%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $36.25
Upside: -22.76%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $104.50
Upside: -61.72%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $7.92
Upside: +1,036.36%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $1.15
Upside: +8,247.83%